Seeking Alpha Seeking Alpha Portfolio App for iPad  The book
value of Cytori (CYTX) common stock is $0.18 per share as of Q4
2011, and I project it will be close to zero at the end of Q1
2012.  Unfortunately for Cytori shareholders, book value
approximates what I believe is fair value of the equity. What
should one pay for a business that, on average, loses 7 million
every quarter for the last 4 years on 2 million in revenue? I
don't believe Cytori is a pipeline "story", so I would submit
that these shares are worthless. And yes, we are short the
stock.  Cytori likes to think they're a leader in regenerative
medicine. I have a few issues with this.  First, regenerative
medicine is a meaningless and embarrassing buzzword that means
nothing. Medicine is medicine, and the goal of any therapy is to
increase the patient's well-being while limiting adverse events.
Using cells as a therapy is not a new idea, so using the word
"regenerative" is both redundant and unnecessary. Actual leaders
in the cell therapy field,